FibroGen's in-development treatment for anemia is still in the midst of Phase III development, but thanks to a legal loophole, the pill has made its way into the world of competitive cycling, where its red blood cell-boosting effects can give athletes an advantage.
Sanofi has gotten a bit of positive reinforcement in its efforts to revive its diabetes business in the U.S. Experimental combo med LixiLan has thrown off some promising results, hitting its primary goal in a late-stage trial.
As the diagnostics industry zeroes in on rapid point-of-care tests, a team of scientists from the Johns Hopkins University is developing an innovative smartphone diagnostic for chlamydia that could improve screening for the disease.
Sanofi's combination of a Type 2 diabetes treatment and a long-acting insulin met its main goal in a Phase III trial, the company said, setting up an FDA application later this year.
Sprint Bioscience (STO:SPRINT) has entered into a cancer research collaboration with Bayer, handing over the rights to an early-stage tumor metabolism program in return for €190 million ($210 million) in upfront and milestone payments.
Diagnostic assays that usually require a desktop reader that costs several thousand dollars can now be done using a 3-D printed plate that attaches to a smartphone. Even better, the accuracy of the results achieved are comparable to standard laboratory equipment.
After winning approval for their PCSK9 drug Praluent last week, longtime partners Sanofi and Regeneron are back at it with a new collaboration. The French pharma giant will pay at least $1.8 billion in a new immuno-oncology deal that includes an early-stage checkpoint inhibitor.
Researchers at MIT and Massachusetts General Hospital have designed an expanding pill that can be easily swallowed but can remain in the stomach potentially for months without obstructing normal gastrointestinal function.
Folding DNA into new, functional shapes isn't a new technique, but researchers at Arizona State University have demonstrated novel design methods that allow them an amount of control over the genetic substance never seen before, creating new three-dimensional shapes that could ultimately be used in drug delivery.
Aegerion Pharmaceuticals CEO Marc Beer has stepped down from his post after reaching a tenuous cease-fire with activist investors, leaving behind a company with an uncertain future.